Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BARE: Enzalutamide in Renal Cell Carcinoma
NCT02885649Phase 1Terminated
- Sponsor
- Rutgers University
- Start
- Dec 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enzalutamide in clear cell renal cell carcinoma (ccRCC), sponsored by Rutgers University. Primary endpoints: Cell proliferation up to 36 months and Tumor apoptosis as measured by annexin up to 36 months. Started Dec 2017; status: terminated.
02
Drugs
enzalutamide
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT02885649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02885649.